FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2057008511> ?p ?o ?g. }

• W2057008511 endingPage "751" @default.
• W2057008511 startingPage "734" @default.
• W2057008511 abstract "The Journal of Clinical PharmacologyVolume 15, Issue 11-12 p. 734-751 Pharmacological Response Data for Comparative Bioavailability Studies of Chlorpromazine Oral Dosage Forms in Humans: I. Pupilometry Dr. V. F. SMOLEN Ph.D., Corresponding Author Dr. V. F. SMOLEN Ph.D. Interdisciplinary Drug Engineering and Assessment Laboratory (IDEAL), School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, Indiana 47907. Department of Industrial and Physical Pharmacy, Purdue University, West Lafayette, Indiana. 47907.Department of Industrial and Physical Pharmacy, Purdue University, West Lafayette, Indiana 47907.Search for more papers by this authorDr. H. R. MURDOCK JR. Ph.D., Dr. H. R. MURDOCK JR. Ph.D. Interdisciplinary Drug Engineering and Assessment Laboratory (IDEAL), School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, Indiana 47907. Division of Biopharmaceutics, Bureau of Drugs, United States Food and Drug Administration, Rockville, Maryland 20852.Search for more papers by this authorW. P. STOLTMAN B.S., W. P. STOLTMAN B.S. Interdisciplinary Drug Engineering and Assessment Laboratory (IDEAL), School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, Indiana 47907.Search for more papers by this authorJ. W. CLEVENGER B.S., J. W. CLEVENGER B.S. Interdisciplinary Drug Engineering and Assessment Laboratory (IDEAL), School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, Indiana 47907.Search for more papers by this authorL. W. COMBS M.D., L. W. COMBS M.D. Interdisciplinary Drug Engineering and Assessment Laboratory (IDEAL), School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, Indiana 47907.Search for more papers by this authorE. J. WILLIAMS Ph.D., E. J. WILLIAMS Ph.D. Interdisciplinary Drug Engineering and Assessment Laboratory (IDEAL), School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, Indiana 47907.Search for more papers by this author Dr. V. F. SMOLEN Ph.D., Corresponding Author Dr. V. F. SMOLEN Ph.D. Interdisciplinary Drug Engineering and Assessment Laboratory (IDEAL), School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, Indiana 47907. Department of Industrial and Physical Pharmacy, Purdue University, West Lafayette, Indiana. 47907.Department of Industrial and Physical Pharmacy, Purdue University, West Lafayette, Indiana 47907.Search for more papers by this authorDr. H. R. MURDOCK JR. Ph.D., Dr. H. R. MURDOCK JR. Ph.D. Interdisciplinary Drug Engineering and Assessment Laboratory (IDEAL), School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, Indiana 47907. Division of Biopharmaceutics, Bureau of Drugs, United States Food and Drug Administration, Rockville, Maryland 20852.Search for more papers by this authorW. P. STOLTMAN B.S., W. P. STOLTMAN B.S. Interdisciplinary Drug Engineering and Assessment Laboratory (IDEAL), School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, Indiana 47907.Search for more papers by this authorJ. W. CLEVENGER B.S., J. W. CLEVENGER B.S. Interdisciplinary Drug Engineering and Assessment Laboratory (IDEAL), School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, Indiana 47907.Search for more papers by this authorL. W. COMBS M.D., L. W. COMBS M.D. Interdisciplinary Drug Engineering and Assessment Laboratory (IDEAL), School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, Indiana 47907.Search for more papers by this authorE. J. WILLIAMS Ph.D., E. J. WILLIAMS Ph.D. Interdisciplinary Drug Engineering and Assessment Laboratory (IDEAL), School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, Indiana 47907.Search for more papers by this author First published: November‐December 1975 https://doi.org/10.1002/j.1552-4604.1975.tb02338.xCitations: 11AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Smolen, V. F.: Theoretical and computational basis for drug bioavailability determinations using pharmacological data. I. General considerations. J. Pharmacokin. & Biopharm. In review. 2 Smolen, V. F.: Theoretical and computational basis for drug bioavailability determinations using pharmacological data. II. Deconvolution methods. J. Pharmacokin. & Biopharm. In review. 3 Smolen, V. F., Kuehn, P. B., and Williams, E. J.: Idealized approach to the optimal design, development, and evaluation of drug delivery systems. I. Drug bioavailability input—pharmacological response output relationships. Drug Develop. Comm. 1: 143 (1975). 4 Smolen, V. F., Kuehn, P. B., and Williams, E. J.: Idealized approach to the optimal design, development, and evaluation of drug delivery systems. II. Optimization of drug bioavailability inputs and invitro drug release testing. Drug Develop. Comm. 1: 231 (1975). 5 Smolen, V. F., and Schoenwald, R. D.: Drug absorption analysis from pharmacological data. I. The method and its confirmation exemplified for a mydriatic drug, tropicamide. J. Pharm. Sci. 60: 96 (1971). 6 Schoenwald, R. D., and Smolen, V. F.: Drug absorption analysis from pharmacological data. II. Transcorneal biophasic availability of tropicamide. J. Pharm. Sci. 60: 1039 (1971). 7 Smolen, V. F., and Schoenwald, R. D.: Drug absorption analysis from pharmacological data. III. Influence of polymers and pH on transcorneal biophasic availability and miotic response of tropicamide. J. Pharm. Sci. 63: 1582 (1974). 8 Smolen, V. F., Murdock, H. R., and Williams, E. J.: Bioavailability analysis of chlorpromazine from pupilometric data. J. Pharm. & Exp. Therap. in press. 9 Smolen, V. F., Williams, E. J., and Kuehn, P. B.: Pharmacokinetics and bioavailability analysis of chorpromazine in animas and humans from pharmacological data. Can. J. Pharm. Sci. in press. 10 Curry, S. H., and Marshall, J. H. L.: Plasma levels of chlorpromazine and some of its relatively non-polar metabolites in psychiatric patients. Life Sciences 7: 9 (1968). 11 Kuehn, P. B., Jhawar, A. K., Weigand, W. A., and Smolen, V. F.: Drug bioavailability input ± pharmacological response output relationships. I. Pharmacokinetics of chlorpromazine induced miotic response in rabbits. J. Pharm. Sci. In review. 12 Smolen, V. F., Jhawar, A. K., Weigand, W. A., Paolino, R. M., and Kuehn, P. B.: Drug bioavailability input ± pharmacological response output relationships. II. Pharmacological response kinetics of chlorpromazine induced rectal temperature depression in rabbits. J. Pharm. Sci. In review. 13 Hollister, L., Curry, S. H., Derr, J., and Kanter, S.: Studies of delayed action medication. V. Clin. Pharm. & Therap. 11: 49 (1970). 14 Sakalis, M. B., Curry, S. H., Gould, G. P., and Lader, M. H.: Physiologic and clinical effects of chlorpromazine and their relationship to plasma level. Clin. Pharm. & Therap. 13: 931 (1972). 15 Curry, S. H.: Action and metabolism of chlorpromazine. In D. S. Davies and B. N. C. Pritchard, eds.: Biological Effects of Drugs in Relation to Their Plasma Concentrations. Baltimore, University Park Press, 1973, p. 201. 16 Smolen, V. F., Barile, R. D., and Theophanous, T. G.: Relationship between dose, effect, time, and biophasic drug levels. J. Pharm. Sci. 61: 467 (1972). 17 Smolen, V. F., Turrie, D. B., and Weigand, W. A.: Drug input optimization: Bioavailability-effected time optimal control of multiple, simultaneous, pharmacological effects and their inter-relationships. J. Pharm. Sci. 61: 1941 (1972). 18 Smolen, V. F., and Weigand, W. A.: Drug bioavailability and pharmacokinetic analysis from pharmacological data. J. Pharmacokin. & Biopharm. 1: 329 (1973). 19 Smolen, V. F.: Quantitative determination of drug bioavailability and pharmacokinetic behavior from pharmacological data for ophthalmic and oral administration of a mydriatic drug. J. Pharm. Sci. 60: 354 (1971). 20 Westlake, W. J.: The design and analysis of comparative blood level trials. In J. Swarbrick, ed.: Current Concepts in the Pharmaceutical Sciences: Dosage Form Design and Bioavailability. Philadelphia, Lea & Febiger, 1973, p. 149. 21 Curry, S. H., D'Mello, A., and Gould, G. P.: Destruction of chlorpromazine during absorption by rat intestine. Brit. J. Pharmacol. 42: 403 (1971). 22 Sugerman, A. A., and Rosen, E.: Absorption efficiency and excretion profile of a prolonged action form of chlorpromazine. Clin. Pharmacol. Therap. 5: 561 (1961). 23 Marks, J. H.: Use of chlorpromazine in radiation sickness and nausea from other causes. New Eng. J. Med. 250: 999 (1954). 24 Daeschner, C. W., Clark, J. L., George, G. Y., and Frankel, R. A.: Chlorpromazine in the control of vomiting in children. Am. J. Dis. of Children 89: 525 (1955). 25 Fink, S., and Winslow, W. A.: Anti-emetic effect of chlorpromazine (Thorazine) in cancer patients. Gastroent. 28: 731 (1955). 26 Meyer, J. H., Kent, B., Knight, R. W., Morris, G., Dizon, M., Rogers, S., and Spurr, C.: Clinical studies of an antiemetic agent, chlorpromazine. Am. J. Med. Sci. 228: 174 (1954). Citing Literature Volume15, Issue11-12November‐December 1975Pages 734-751 ReferencesRelatedInformation" @default.
• W2057008511 created "2016-06-24" @default.
• W2057008511 creator A5006693382 @default.
• W2057008511 creator A5015504827 @default.
• W2057008511 creator A5017279238 @default.
• W2057008511 creator A5031193770 @default.
• W2057008511 creator A5032043576 @default.
• W2057008511 creator A5046642091 @default.
• W2057008511 date "1975-11-12" @default.
• W2057008511 modified "2023-10-03" @default.
• W2057008511 title "Pharmacological Response Data for Comparative Bioavailability Studies of Chlorpromazine Oral Dosage Forms in Humans: I. Pupilometry" @default.
• W2057008511 cites W1917205856 @default.
• W2057008511 cites W1963858686 @default.
• W2057008511 cites W2008464929 @default.
• W2057008511 cites W2018456429 @default.
• W2057008511 cites W2030727741 @default.
• W2057008511 cites W2045359277 @default.
• W2057008511 cites W2050144590 @default.
• W2057008511 cites W2053567945 @default.
• W2057008511 cites W2058996434 @default.
• W2057008511 cites W2061967963 @default.
• W2057008511 cites W2070653519 @default.
• W2057008511 cites W2070966146 @default.
• W2057008511 cites W2094357608 @default.
• W2057008511 cites W2155119699 @default.
• W2057008511 cites W2298753418 @default.
• W2057008511 cites W2396006943 @default.
• W2057008511 cites W2417724689 @default.
• W2057008511 doi "https://doi.org/10.1002/j.1552-4604.1975.tb02338.x" @default.
• W2057008511 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1104666" @default.
• W2057008511 hasPublicationYear "1975" @default.
• W2057008511 type Work @default.
• W2057008511 sameAs 2057008511 @default.
• W2057008511 citedByCount "9" @default.
• W2057008511 countsByYear W20570085112018 @default.
• W2057008511 countsByYear W20570085112020 @default.
• W2057008511 crossrefType "journal-article" @default.
• W2057008511 hasAuthorship W2057008511A5006693382 @default.
• W2057008511 hasAuthorship W2057008511A5015504827 @default.
• W2057008511 hasAuthorship W2057008511A5017279238 @default.
• W2057008511 hasAuthorship W2057008511A5031193770 @default.
• W2057008511 hasAuthorship W2057008511A5032043576 @default.
• W2057008511 hasAuthorship W2057008511A5046642091 @default.
• W2057008511 hasConcept C112705442 @default.
• W2057008511 hasConcept C181389837 @default.
• W2057008511 hasConcept C2778775820 @default.
• W2057008511 hasConcept C71924100 @default.
• W2057008511 hasConcept C77281830 @default.
• W2057008511 hasConcept C98274493 @default.
• W2057008511 hasConceptScore W2057008511C112705442 @default.
• W2057008511 hasConceptScore W2057008511C181389837 @default.
• W2057008511 hasConceptScore W2057008511C2778775820 @default.
• W2057008511 hasConceptScore W2057008511C71924100 @default.
• W2057008511 hasConceptScore W2057008511C77281830 @default.
• W2057008511 hasConceptScore W2057008511C98274493 @default.
• W2057008511 hasIssue "11-12" @default.
• W2057008511 hasLocation W20570085111 @default.
• W2057008511 hasLocation W20570085112 @default.
• W2057008511 hasOpenAccess W2057008511 @default.
• W2057008511 hasPrimaryLocation W20570085111 @default.
• W2057008511 hasRelatedWork W1555144605 @default.
• W2057008511 hasRelatedWork W1970245702 @default.
• W2057008511 hasRelatedWork W1970331292 @default.
• W2057008511 hasRelatedWork W2004325424 @default.
• W2057008511 hasRelatedWork W2031821162 @default.
• W2057008511 hasRelatedWork W2080955156 @default.
• W2057008511 hasRelatedWork W2379311614 @default.
• W2057008511 hasRelatedWork W2400119402 @default.
• W2057008511 hasRelatedWork W2606334551 @default.
• W2057008511 hasRelatedWork W2776273895 @default.
• W2057008511 hasVolume "15" @default.
• W2057008511 isParatext "false" @default.
• W2057008511 isRetracted "false" @default.
• W2057008511 magId "2057008511" @default.
• W2057008511 workType "article" @default.